# Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

> **NCT06770257** · PHASE2 · WITHDRAWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China**

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** daunorubicin, cytarabine liposomes
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06770257
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-10
- **Primary completion:** 2026-12-10
- **Final completion:** 2027-06-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The project was terminated as the genetic office did not approve it.
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770257, "Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06770257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*